Experimental eye injection offers hope for blinding genetic diseases
NCT ID NCT05282953
Summary
This early-stage study is testing the safety and effects of an experimental drug called KIO-301, which is injected into the eye. It aims to help adults aged 18-80 who have lost significant vision due to genetic eye diseases like retinitis pigmentosa or choroideremia. The main goal is to see if the treatment is safe and well-tolerated, while also checking if it might improve vision function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harley Eye Clinic
COMPLETEDNorth Adelaide, South Australia, 5006, Australia
-
Royal Adelaide Hospital
RECRUITINGAdelaide, South Australia, 5000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Save Sight Institute
RECRUITINGSydney, New South Wales, 2001, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.